Status:
UNKNOWN
Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate
Lead Sponsor:
West China Hospital
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
Neoadjuvant treatment before radical prostatectomy has been proven to provide benefits on peri-operation results, especially on reduction of tumor volume and minimization of biochemical recurrence. Th...
Detailed Description
IDC-P is an adverse pathological entity of prostate cancer, characterized by the growth of malignant cells in pre-existing prostatic ducts and acini, and is present in high-grade disease and associate...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Histologically or cytologically diagnosis of prostate cancer with positive IDC-P status
- High-risk localized prostate cancer, defined by either: Tumor stage ≥T3a by digital rectal examination, or Primary tumor Gleason score ≥ 8, or PSA \> 20 ng/mL
- No evidence of metastases
- The ECOG score of the patient is ≤2
- Expected survival over 5 years
- Patients must participate voluntarily and sign an informed consent form (ICF), indicating that they understand the purpose and required procedures of the study, and are willing to participate in. Patients must be willing to obey the prohibitions and restrictions specified in the research protocol
- Agree to collect the tumor tissue and blood samples needed for the research and apply them to related study
- Adequate hematologic, renal and hepatic function:
- Absolute neutrophil count \[ANC\] ≥1.5 x 10\^9/L
- Platelet count \[PLT\] ≥100 x 10\^9/L
- Hemoglobin \[HGB\] ≥9 g/dL
- Serum Total bilirubin \[TBIL\] ≤1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) \< 2.5 x ULN
- Serum albumin \[ALB\] ≥2.8 g/dL
- Serum Creatinine ≤ 1.5 x ULN
- Creatinine Clearance ≥ 40 mL/min
Exclusion
- Prior androgen deprivation therapy (medical or surgical), radiation therapy or chemotherapy for prostate cancer
- Evidence of metastatic disease (M1) on imaging studies
- Pathological finding consistent with small cell, ductal or neuroendocrine carcinoma of the prostate
- Major surgery or severe trauma within 30 days before enrollment
- Patients with severe or uncontrolled concurrent，including but not limited to：
- Severe or uncontrolled concurrent infections
- Human immunodeficiency virus \[HIV\] infection positive
- Suffer from acute or chronic active hepatitis B (HBsAg positive and HBV DNA\>1x10\^3/mL) Or acute or chronic active hepatitis C (HCV antibody positive and HCV RNA\>15 IU/mL)
- Active tuberculosis, etc
- Abnormal cardiac function as manifested by NYHA (New York Heart Association) class III or IV heart failure，or clinically significant ventricular arrhythmias
- Uncontrolled hypertension（Systolic blood pressure≥160mmHg or Diastolic blood pressure≥100mmHg）
- Severe or unstable angina, myocardial infarction，arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks) Occurred within 6 months before enrollment
- Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study
- Any condition that in the opinion of the investigator, would preclude participation in this study
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04736108
Start Date
May 1 2021
End Date
December 1 2024
Last Update
February 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital
Chengdu, Sichuan, China, 610000